MKMelanie Kessler

Melanie Kessler

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Melanie Kessler has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Andreas Mühlemann

    Idorsia Pharmaceuticals Ltd, Drug Discovery and Preclinical Research & Development, Hegenheimermattweg 91, Allschwil CH-4123, Switzerland

    2 shared publications
  • Caroline Deymier

    Idorsia Pharmaceuticals Ltd, Department of Drug Discovery, CNS-Pharmacology Division, Allschwil, Switzerland

    2 shared publications
  • Catherine Roch

    Idorsia Pharmaceuticals Ltd, Drug Discovery and Preclinical Research & Development, Hegenheimermattweg 91, Allschwil CH-4123, Switzerland

    2 shared publications
  • Catherine Roch

    Idorsia Pharmaceuticals Ltd, Department of Drug Discovery, CNS-Pharmacology Division, Allschwil, Switzerland

    2 shared publications
  • Hélène Roellinger

    Idorsia Pharmaceuticals Ltd, Department of Drug Discovery, CNS-Pharmacology Division, Allschwil, Switzerland

    2 shared publications
  • Jens-Uwe Peters

    Idorsia Pharmaceuticals Ltd, Drug Discovery and Preclinical Research & Development, Hegenheimermattweg 91, Allschwil CH-4123, Switzerland

    2 shared publications

Latest Publications

  • IDOR-1104-0086, a novel Kv7 channel activator with antiseizure effects in rodents

    by Melanie Kessler, Andreas Mühlemann, Malgorzata Anna Mis, Romain Siegrist, Swen Seeland, Caroline Deymier, Cary-Ann Mathieu, Hélène Roellinger, Tsvetomira Atanasova, Catherine Roch, et al.


  • Discovery and In-Vivo Characterization of Kv7 Channel Openers through a Phenotypic Approach

    by Romain Siegrist, Olivier Bezençon, Caroline Deymier, Melanie Kessler, Malgorzata Anna Mis, Andreas Mühlemann, Jens-Uwe Peters, Catherine Roch, Swen Seeland

    Despite the availability of approximately 30 antiseizure drugs (ASDs), epilepsy remains a major unmet clinical need, with approximately 30% of epileptic patients experiencing uncontrolled seizures despite an adequately chosen treatment. Polypharmacology is a common feature of many ASDs and polypharmacy is a usual practice to treat epileptic patients. Several approved ASDs were originally discovered through phenotypic screening in rodent models of seizures. To overcome the technical and ethical challenges associated with animal testing, we developed an in vitro assay that recapitulates seizure-related neuronal hyperexcitability phenotypes in a dish. Using this unbiased assay, a new class of urea compounds was discovered. Through optimization, compound 31 (IDOR-1104–0086) was identified as an orally bioavailable and brain-penetrant compound with in vivo efficacy in two rodent models of epilepsy and a favorable tolerability profile. Target deconvolution revealed that these ureas exert their antiseizure effects through activation of KV7 potassium channels, a mechanism consistent with the modulation of neuronal excitability.


  • Discovery of a New Class of Orexin 2 Receptor Agonists as a Potential Treatment for Narcolepsy

    by Davide Pozzi, Romain Siegrist, Jens-Uwe Peters, Christopher Kohl, Andreas Mühlemann, Simon Schlienger, Caterina Torrisi, Eleanor Lindenberg, Melanie Kessler, Catherine Roch

    The orexinergic system, projecting from the lateral hypothalamus, operates through two receptors, orexin receptor type-1 (OX1) and orexin receptor type-2 (OX2), stabilizing wakefulness, mainly via OX2. Narcolepsy Type 1 (NT1) is characterized by excessive sleepiness and cataplexy, and is linked to a loss of orexin-producing neurons. Current therapies manage the symptoms but do not address the underlying cause of the disease. For example, psychostimulants (e.g., modafinil) reduce excessive daytime sleepiness (EDS) and sodium oxybate (gammaaminobutyric acid receptor agonist) reduces both EDS and cataplexy. Despite decades of research, no small-molecule OX2 agonist has reached the market. This study presents the discovery of two new brain-penetrant, orally bioavailable OX2 agonists with a phenylglycine-like scaffold. These compounds stabilized wakefulness and reduced cataplexy in a mouse model of NT1. In healthy dogs, they increased time in wakefulness. These results highlight their potential as treatment for narcolepsy and other types of hypersomnolence.


  • Antiseizure potential of the triple T‐type calcium channel blocker ACT ‐709478 (apinocaltamide) in rodent models

    by Melanie Kessler, Hélène Roellinger, Corinne Roucard, Michel Alexander Steiner, Catherine Roch

    Objective: T‐type Ca 2+ channels in the brain contribute to the generation of spike‐and‐wave discharges (SWDs). Absence seizures are defined by the occurrence of SWDs and are associated with impairment of consciousness. ACT‐709478 is a selective and highly potent blocker of the low‐voltage‐activated T‐type Ca 2+ channels, Ca v 3.1, Ca v 3.2, and Ca v 3.3, with no relevant activity on other targets. Our aim was to investigate the efficacy of ACT‐709478 in reducing absence‐like and other types of seizures in rodents. Methods: We studied the effect of oral ACT‐709478 on SWDs in two models of absence‐like epilepsy, Wistar Albino Glaxo from Rijswijk (WAG/Rij) rats and Genetic Absence Epilepsy Rats from Strasbourg (GAERS), and compared it to first‐line monotherapy. We also assessed the potential of ACT‐709478 to reduce generalized convulsive seizures in audiogenic seizure‐sensitive (AGS) mice and in the maximal electroshock threshold test (MEST) in mice, as well as in one model of focal onset seizures, the amygdala kindling rat model. We tested combinations of ACT‐709478 with the broadly used first‐line medication valproate in AGS mice. Results: ACT‐709478 suppressed SWDs in WAG/Rij rats and GAERS with efficacy equivalent to or superior to that of first‐line monotherapy. ACT‐709478 also reduced the severity of generalized convulsive seizures in the AGS mouse model and the MEST in mice, albeit at higher concentration. ACT‐709478 had synergistic effects against generalized convulsive seizures, when combined with valproate, and had no effect on focal onset seizures. Significance: Based on its efficacy profile in rodent models, ACT‐709478 represents a promising drug candidate for the treatment of absence epilepsy such as childhood absence epilepsy or syndromes featuring SWDs. It could possibly also be beneficial for epileptic syndromes presenting with additional seizure types.